|
There has been a growing trend towards natural medicines and the use of
dietary supplements for modern healthcare, as people throughout the world
are becoming increasingly dissatisfied with the possible side-effects, lack
of noticeable long-term results and high cost associated with allopathic
drugs. Herbal products have provided a more natural and often more effective
alternative.
Cadila Pharmaceuticals uses the ancient Indian medicinal science of Ayurveda
to make herbal formulations with clinically proven efficacy. The Company has
an experienced phytochemistry research team since 1983 and has developed 30
unique herbal products. A thorough
understanding of the medicinal value of herbs is achieved in
order to work on herbal drugs and to initiate phytochemical
research. Formulation is done through the exact process, as
per the ancient science of Ayurveda.
Phytochemistry
Department activities:
-
Drug development
from natural origin
-
Establishment
of botanical identity of herbs
-
Phytochemical
isolation and identification
-
Screening of
herbal formulations and isolated compounds
-
Coordination
of clinical pharmacology and clinical trials
-
Development and
manufacturing of herbal dietary supplements
-
Analytical Research
of & designation of herbs
|
|
 |
In line with our vision to
be significant global player by 2010 A.D., Cadila
Pharmaceuticals is fast emerging as a true Indian multinational.
As part of our strategy, we have wholly owned subsidiaries,
joint ventures, strategic alliances, contract manufacturing, own
marketing offices in 4 countries and have significant presence
in over 46 countries across the globe. Our business revolves
around the exports of formulations, bulk actives, hospital
disposables, veterinary formulations and pharmaceutical
machinery manufacturing.
Besides a significant presence in the Americas, CIS Countries,
Africa, Central and South-East Asia, Oceanic Countries, Japan,
Middle East and Europe, the company has offices in USA, Japan,
Kenya, Nigeria, Russia, Kazakhstan and Ukraine.
The International SBU plans to expand operations to more than
100 countries by 2010.
The focus is on building brands in the following therapeutic
segments:
-
Anti-Infective
-
Gastrointestinal
-
Analgesic/Anti-inflammatory
-
Cardiovascular
-
Respiratory
-
Ophthalmology
-
Bio-technical Products
Alliances exist with
regional majors in the form of International marketing, joint
ventures and contract manufacturing. More such collaborations
are underway to expand supply chain network and facilitate
extensive market coverage. An ultra-modern formulations
manufacturing facility conforming to the exacting standards of
WHO-GMP, USFDA, MHRA-UK, MCC-South Africa, TGA-Australia,
ANVISA- Brazil, EU GMP, ISO 9002 and Japanese GMP is a
value-addition to the International SBU in flexing its muscles
in the overseas arena. This SBU has been honoured with the
Chemexcil Award, 2000-01 and Niryat Shree Award from FIEO, for
the year 2001-02.
With its basic philosophy of giving the best to the world at an
affordable price, Cadila Pharmaceuticals continues to make a
difference in the lives of millions, while carving a niche for
Indian Pharmaceuticals exports, globally |
